DPA Test

If you have ever looked at an omega-3 blood test, you probably focused on EPA and DHA. Those two get most of the attention, but there is a third long-chain omega-3 sitting quietly between them that may matter just as much for your long-term health. DPA (docosapentaenoic acid) is the omega-3 fatty acid your body makes from EPA on the way to building DHA, and large pooled analyses involving tens of thousands of people have linked higher circulating DPA to lower risk of heart attack, stroke, heart failure, type 2 diabetes, chronic kidney disease, and premature death.

What makes DPA interesting is that it appears to carry its own protective biology, separate from EPA and DHA. It produces a unique set of inflammation-resolving molecules, and in several major studies its association with better outcomes held up even after accounting for the other two omega-3s. Knowing your DPA level gives you a more complete picture of your omega-3 status than any single marker can.

What DPA Is and How It Differs from EPA and DHA

DPA is a 22-carbon omega-3 polyunsaturated fatty acid (a type of fat with multiple flexible bonds in its carbon chain). Your liver builds it by lengthening EPA (eicosapentaenoic acid), and from there it can either be converted forward into DHA (docosahexaenoic acid) or recycled back into EPA. This two-way conversion makes DPA a kind of reserve tank: when your body needs more EPA or more DHA, it can draw on its DPA stores.

You get DPA from eating fatty fish, other seafood, and, to a lesser extent, lean red meat. Once absorbed, it is incorporated into the membranes of your red blood cells and other tissues, where it can be released and converted into specialized pro-resolving mediators. These are molecules your immune system uses to switch off inflammation once its job is done, rather than letting it smolder indefinitely. DPA generates its own distinct versions of these mediators, which is why researchers believe it has biological effects beyond simply being a stepping stone between EPA and DHA.

Heart Disease and Coronary Risk

The most extensive evidence on DPA and heart disease comes from a pooling project that combined individual-level data from 19 prospective cohorts. That analysis found that higher circulating levels of seafood-derived omega-3 fatty acids, including DPA, were associated with lower coronary heart disease risk, with the strongest associations seen when omega-3s were measured in blood phospholipids (the fat-containing molecules that make up cell membranes) and total plasma.

A separate study of about 2,500 adults in the Framingham Heart Study tracked erythrocyte (red blood cell) omega-3 levels and found that higher long-chain omega-3 fatty acid levels were inversely associated with both cardiovascular disease and all-cause mortality. In a case-control study of 192 people, those with early-onset coronary artery disease (heart disease appearing before age 55 in men or 65 in women) had significantly lower serum levels of DPA, DHA, and EPA compared to matched controls.

If your DPA level is low alongside low EPA and DHA, that pattern points to an omega-3 deficit that standard cholesterol panels would never flag. It suggests your cell membranes and blood vessels are running without one of their key protective inputs.

Stroke Risk

DPA stands out in the stroke data because it was independently linked to protection. An analysis pooling three large US cohorts found that higher circulating DPA and DHA were each associated with a lower risk of atherothrombotic stroke (caused by plaque buildup in brain arteries) and cardioembolic stroke (caused by clots from the heart). The study noted that DPA and DHA appeared to act through different pathways, suggesting they are not simply substitutes for one another.

This is meaningful because stroke prevention has traditionally focused on blood pressure, cholesterol, and blood thinners. Omega-3 status, and DPA specifically, represents a modifiable risk factor that conventional screening does not capture.

Heart Failure

In the Cardiovascular Health Study, a cohort of 2,735 older adults followed over many years, higher circulating EPA and DPA levels were each associated with a lower incidence of congestive heart failure. DPA was specifically called out as independently protective alongside EPA, even after adjustment for other risk factors. This suggests that the anti-inflammatory and membrane-stabilizing properties of DPA may help the heart muscle resist the progressive weakening that leads to heart failure.

Type 2 Diabetes

A large individual-participant pooling project across 20 prospective cohorts examined circulating omega-3 biomarkers and the risk of developing type 2 diabetes. Higher levels of seafood-derived omega-3 fatty acids, specifically EPA, DPA, DHA, and their combined total, were each associated with lower type 2 diabetes risk. The plant-derived omega-3 ALA (alpha-linolenic acid) did not show the same association, which reinforces the idea that the long-chain forms found in seafood, including DPA, have distinct metabolic effects.

Kidney Disease

A pooled analysis of 19 cohorts found that higher levels of seafood-derived omega-3 fatty acids were associated with a lower risk of developing chronic kidney disease. Plant-derived omega-3s showed no such association. Because the kidneys are highly vascular organs sensitive to inflammation, the anti-inflammatory properties of long-chain omega-3s like DPA may help preserve kidney function over time, particularly in people with other risk factors such as high blood pressure or diabetes.

All-Cause Mortality

A pooled analysis of 14 prospective cohorts examined circulating omega-3 fatty acid levels and total and cause-specific mortality. Higher levels of long-chain omega-3 polyunsaturated fatty acids were strongly associated with lower all-cause mortality and lower death rates from specific causes. In a separate analysis of over 8,500 adults with existing cardiometabolic disease (conditions like diabetes, heart disease, or metabolic syndrome), dietary DPA intake was specifically associated with reduced all-cause mortality, and both EPA and DPA intake were linked to lower cardiovascular death.

These findings are consistent across studies from different countries, populations, and measurement methods, which strengthens confidence that the association between higher DPA and longer life is real, not a statistical artifact.

Cancer: A More Complex Picture

The relationship between DPA and cancer is not straightforward. A meta-analysis found that higher intake of EPA and DHA was associated with a lower risk of colorectal cancer. However, a Mendelian randomization study (which uses genetic variants as proxies for lifelong exposure) found that genetically elevated DPA was positively associated with lung cancer risk. Mendelian randomization studies are useful for suggesting causal direction, but they model lifelong genetic predisposition rather than the effect of changing your omega-3 intake as an adult.

This does not mean eating fish causes lung cancer. It means the relationship between omega-3 fatty acids and cancer risk varies by cancer type and by the specific fatty acid involved. For now, the cardiovascular and metabolic benefits of DPA are far better supported than any cancer risk signal, but this is an area where more research is needed.

Atrial Fibrillation: No Increased Risk

One concern that has surfaced in omega-3 research is whether high-dose supplementation might trigger atrial fibrillation (an irregular heart rhythm). A large meta-analysis examining omega-3 fatty acid biomarkers (including EPA, DPA, and DHA) and incident atrial fibrillation found no association between higher circulating levels and increased risk of developing this condition. This is reassuring for people whose blood levels are naturally high from diet.

Reference Ranges

DPA does not yet have standardized clinical cutpoints endorsed by major medical guidelines. Unlike total cholesterol or blood sugar, there is no universally agreed-upon threshold that separates "optimal" from "low." The research consistently shows that higher circulating DPA is associated with better outcomes, but the exact numbers vary depending on the lab method, the type of blood sample (whole blood, plasma, or red blood cell membranes), and the population studied.

Your lab will report your result as a percentage of total fatty acids or as an absolute concentration. Because assay methods differ between labs, the most reliable way to interpret your DPA is to compare it within the same lab over time, rather than against a single universal target. A result in the lower portion of your lab's reference range, especially combined with low EPA and DHA, warrants attention.

Tracking Your Trend

A single DPA reading is a snapshot, not a verdict. Your omega-3 fatty acid levels reflect weeks to months of dietary intake and metabolic processing, not what you ate yesterday. This makes DPA more stable than many blood markers, but it also means a single reading may not capture your true baseline if your diet has recently changed.

Get a baseline reading, then retest in 3 to 4 months if you are making dietary changes or starting omega-3 supplementation. After that, annual testing is a reasonable cadence to confirm your levels are holding steady. Watching the trend matters more than obsessing over any single number: a DPA that is rising over time tells you that your dietary strategy is working, while a DPA that is falling despite supplements may signal absorption issues or an imbalance in your omega-3 intake.

Because DPA can convert back and forth between EPA and DHA, it is most informative when interpreted alongside those two markers. A high EPA with low DPA might suggest your body is rapidly converting DPA forward to DHA. A low reading across all three signals a genuine omega-3 deficit.

When Results Can Be Misleading

DPA measured in whole blood (which captures red blood cell membrane fatty acids) reflects your intake over the past 2 to 3 months, similar to how HbA1c reflects blood sugar over time. This long integration window makes it relatively resistant to day-to-day fluctuations, but a few things can still distort results.

• Recent dietary shift: If you dramatically increased or decreased seafood intake in the past 2 to 3 weeks, your reading may not yet reflect the new pattern. Red blood cell membranes turn over slowly, so it takes 8 to 12 weeks for a dietary change to fully register.
• Acute illness or surgery: Systemic inflammation can temporarily alter fatty acid metabolism and distribution. If you have been recently ill or had surgery, wait at least 4 to 6 weeks before testing.
• Lab method differences: Different labs use different techniques to measure fatty acids (gas chromatography, mass spectrometry, or other methods). Results from one lab may not be directly comparable to results from another. Always retest at the same lab when tracking your trend.

What to Do With Your Results

If your DPA is in the lower portion of the range, the first step is to look at the full omega-3 picture: your EPA, DHA, and Omega-3 Index. A pattern of low levels across the board suggests insufficient dietary intake of long-chain omega-3s from seafood. If only DPA is low while EPA and DHA are adequate, that is a less common pattern that may reflect individual variation in the enzymes that elongate and convert these fatty acids.

For someone with low omega-3 levels and existing cardiovascular risk factors (high blood pressure, elevated cholesterol, family history of heart disease, or prediabetes), this result adds urgency to dietary changes and may warrant a conversation with a cardiologist or lipidologist about whether higher-dose omega-3 supplementation is appropriate. Pair your omega-3 results with inflammatory markers like hs-CRP (high-sensitivity C-reactive protein, which measures low-grade inflammation) and a lipid panel to build a more complete risk profile.

If your levels are already in the upper range, that is a strong signal that your current dietary pattern is working. Continue what you are doing and retest annually to confirm stability.